clinical trial · NCT05151731
A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema
Diabetic Macular EdemaVamikibartRanibizumabSham Procedure
brief summary
Study BP43445 is a phase II, multicenter, randomized, double-masked, active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of vamikibart administered intravitreally in participants with diabetic macular edema. Only one eye will be chosen as the study eye. The duration of the study will be up to 76 weeks.
started
Dec 31, 2021
primary completion
Nov 6, 2024
completion
Apr 21, 2025
last updated
May 11, 2026
official title
A Phase II, Multicenter, Randomized, Double Masked, Active Comparator-Controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7200220 Administered Intravitreally in Patients With Diabetic Macular Edema
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol